Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for Rifampicin-Resistant Tuberculosis | Kisho | Kisho

Back to Rifampicin-Resistant Tuberculosis

Rifampicin-Resistant Tuberculosis — NIH Grants & Funding

Active and recent NIH-funded research on Rifampicin-Resistant Tuberculosis. Data from NIH RePORTER, last 36 months.

MONDO:0100479

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

Rifampicin-Resistant Tuberculosis has active NIH research funding with 7 funded grants totaling $6.8M.

7funded grants from NIH

Portfolio: $2.6MCumulative: $6.8M5 active2 completed9 PIs7 institutions

By Research Theme

Clinical

Translational

Epi / Nat. History

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$1.7M

FY22

$463K

FY23

$1.4M

FY24

$2.3M

FY25

$915K

FY26

By Funding Mechanism

R01

K43

N01

R21

Funding Gap Analysis

Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Rifampicin-Resistant Tuberculosis. Strongest funded area: Clinical Research. Largest gap: Basic Science.

Biomarker / DiagnosticsPublished, Not NIH-Funded

9 publications in Diagnostic / Biomarker but no NIH-funded grants found in Biomarker / Diagnostics for rifampicin-resistant tuberculosis. Existing research activity suggests this may be a viable area for grant applications.

Basic SciencePublished, Not NIH-Funded

19 publications in Basic Science / Preclinical but no NIH-funded grants found in Basic Science for rifampicin-resistant tuberculosis. Existing research activity suggests this may be a viable area for grant applications.

Adjacent Research(12 grants)

These grants mention Rifampicin-Resistant Tuberculosis as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(12)

OtherR01Active

Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas

RESTREPO, BLANCA et al.·TEXAS BIOMEDICAL RESEARCH INSTITUTE·SAN ANTONIO, TX

$848,724 (FY2025)

NIH RePORTER

OtherR01Active

Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes

Larsen, Michelle et al.·ALBERT EINSTEIN COLLEGE OF MEDICINE·BRONX, NY

$846,347 (FY2025)

NIH RePORTER

OtherR01Active

Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions.

Alland, David·RUTGERS BIOMEDICAL AND HEALTH SCIENCES·Newark, NJ

$782,450 (FY2026)

NIH RePORTER

OtherR01Active

Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods

Franke, Molly·HARVARD MEDICAL SCHOOL·BOSTON, MA

$739,542 (FY2024)

NIH RePORTER

OtherR01Active

Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood

Huang, Zhen et al.·TULANE UNIVERSITY OF LOUISIANA·NEW ORLEANS, LA

$722,477 (FY2025)

NIH RePORTER

OtherR01Active

Evolution, transmission, and control of drug-resistant tuberculosis

COHEN, THEODORE·YALE UNIVERSITY·NEW HAVEN, CT

$665,566 (FY2025)

NIH RePORTER

OtherR01Active

Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa

O'Donnell, Max·COLUMBIA UNIVERSITY HEALTH SCIENCES·NEW YORK, NY

$223,142 (FY2026)

NIH RePORTER

OtherR01Active

Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa

Gandhi, Neel et al.·COLUMBIA UNIVERSITY HEALTH SCIENCES·NEW YORK, NY

$202,214 (FY2026)

NIH RePORTER

OtherK43Active

Development of a Next-generation Rapid Phenotypic Assay for Drug-Resistant M. tuberculosis

Klopper, Marisa·STELLENBOSCH UNIVERSITY·Stellenbosch

$106,193 (FY2025)

NIH RePORTER

OtherR01Completed

Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection

Engelthaler, David et al.·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$736,217 (FY2023)

NIH RePORTER

Kisho

Rifampicin-Resistant Tuberculosis — NIH Grants & Funding

Funding Landscape

By Research Theme

Funding by Fiscal Year

By Funding Mechanism

Funding Gap Analysis

Adjacent Research(12 grants)

Other(12)

Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas

Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes

Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions.

Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods

Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood

Evolution, transmission, and control of drug-resistant tuberculosis

Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa

Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa

Development of a Next-generation Rapid Phenotypic Assay for Drug-Resistant M. tuberculosis

Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection

Top Funded Institutions

Top Principal Investigators